#USA #Germantown #Precigen #RRPF #RRP Awareness

Recognizing International RRP Awareness Day

On June 11, organizations around the world come together to observe International Recurrent Respiratory Papillomatosis (RRP) Awareness Day. This year, Precigen, Inc., a biopharmaceutical company dedicated to innovative precision medicines, along with the Recurrent Respiratory Papillomatosis Foundation (RRPF), has intensified their collaborative efforts to elevate the voices of those affected by this rare chronic illness.

What is RRP?

RRP is a debilitating condition caused by types 6 and 11 of the human papillomavirus (HPV), leading to the formation of benign tumors in the respiratory tract that can disrupt a person's voice, affect their breathing, and hinder overall quality of life. Those living with RRP may face numerous challenges, including repeated surgical interventions and societal misunderstanding of their condition. There are an estimated 27,000 adults in the U.S. suffering from RRP, with more than 170,000 affected globally, indicating the importance of awareness gatherings like this one.

A Platform for Patient Narratives

This year’s RRP Awareness Day emphasizes the importance of personal accounts from patients, caregivers, and healthcare professionals involved in RRP management. Kim McClellan, President of the RRPF, stated, “RRP Awareness Day is about helping patients and families feel seen, heard, and supported.” By amplifying the voices within the RRP community, this initiative aims to foster understanding of the struggles faced daily by individuals affected by the disease.

The campaign hub at rrpawareness.org serves as a resource, offering community testimonials, videos, and narratives that highlight the lived experiences of people battling RRP. The goal is to shed light on the burden this condition places on individuals and their families, ultimately driving a collective effort for broader recognition and support.

A Historic Milestone in Treatment

In a promising development for the RRP community, the U.S. Food and Drug Administration (FDA) approved Precigen's HPV-specific immunotherapy in August 2025, marking a pivotal moment in over a century of RRP treatment history. This is the first-ever approved therapy addressing RRP in adults. Helen Sabzevari, PhD, CEO of Precigen, reiterated the significance of this milestone: “RRP Awareness Day is a powerful reminder that scientific progress begins with listening to patients and understanding the burden they carry every day.” This approved treatment not only provides hope for those suffering but also highlights the critical need for ongoing research and development in the field.

Looking Forward

As organizations like Precigen and RRPF continue their partnership, it is essential for the RRP community and allies to engage in these awareness campaigns actively. Learning more about RRP, sharing stories, and advocating for improved healthcare pathways can usher in a more informed, compassionate society that acknowledges and assists those affected.

Individuals and families seeking to gain deeper insights into RRP or share their stories are encouraged to visit rrpawareness.org as their contributions are vital in the fight against this rare disease. By boosting awareness, we can move towards a future where RRP is understood better, and those affected receive the support they need.

Conclusion

Awareness campaigns like International RRP Awareness Day are instrumental in building a foundation of support and understanding for individuals grappling with RRP. The collaboration between Precigen and RRPF exemplifies the power of collective voices in advancing treatment and fostering community solidarity. By continuing to elevate these narratives, we ensure that no one affected by RRP feels alone in their struggle.